RPG Life Sciences Expands API Portfolio with Rs 135 Crore Acquisition

RPG Life Sciences will acquire the API and intermediates business of Raghava Life Sciences for Rs 135 crore. The transaction is structured as a slump sale involving manufacturing facilities, an R&D lab, and 29 API products.

Reader Takeaway: The acquisition scales API capacity and product variety immediately, though successful integration remains a performance watchpoint.

What just happened

RPG Life Sciences, through its wholly-owned subsidiary RPG Active Pharma Limited, has signed a business transfer agreement to acquire the API and intermediates operations of Raghava Life Sciences. The deal is an asset-based acquisition (slump sale) rather than an equity purchase, ensuring the company gains direct control over infrastructure and intellectual property without inheriting the parent company's shareholding liabilities.

Why this matters

For RPG Life Sciences, this deal is a strategic push to strengthen its presence in the Active Pharmaceutical Ingredient (API) space. By acquiring 29 molecules—22 of which are already commercialized—the firm gains immediate revenue potential and expanded R&D infrastructure. The target business reported an unaudited revenue of Rs 19 crore for FY26, providing a ready-made operational footprint.

Risks to watch

While the company expects the deal to close within 30 days, completion remains subject to customary closing conditions and local regulatory approvals. Investors should monitor the timeline for potential delays in transfer of permits or operational handover. As with any acquisition, the efficiency with which RPG integrates these new manufacturing sites into its existing supply chain will determine the long-term impact on margins.

What to track next

Watch for the official closure announcement from the company within the month. Future analyst calls should shed more light on how the newly acquired products will fit into the company's existing marketing and manufacturing distribution network.